Fig. 4: Tumour response. | British Journal of Cancer

Fig. 4: Tumour response.

From: Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

Fig. 4

Maximum percentage change in tumour size from baseline and best overall response is shown for patients (full analysis set) receiving a berzosertib + gemcitabine (n = 44) and b berzosertib + gemcitabine + cisplatin (n = 7). The dashed line at 20% represents PD, whereas the dashed line at −30% represents PR. Patients with PR had the following primary tumour types: anon-small-cell lung cancer; bcarcinoma (unknown primary origin); chead and neck cancer; dBRCA2 mutation-positive breast cancer; ecolorectal cancer. cis cisplatin, gem gemcitabine, PD progressive disease, PR partial response, SD stable disease.

Back to article page